Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC
Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms
touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY
In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients.
Course director…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.